Merck And Co
Merck & Co., Inc., commonly referred to as Merck, is a leading global healthcare company headquartered in the United States. Founded in 1891, Merck has established itself as a pioneer in the pharmaceutical industry, focusing on innovative medicines, vaccines, and biologic therapies. With a strong presence in North America, Europe, and Asia, the company is dedicated to improving health outcomes worldwide. Merck's core products include groundbreaking treatments in oncology, infectious diseases, and vaccines, notably the HPV vaccine Gardasil and the cancer immunotherapy Keytruda. These offerings are distinguished by their commitment to research and development, which has led to numerous key milestones in medical advancements. As a market leader, Merck consistently ranks among the top pharmaceutical companies globally, recognised for its contributions to public health and its robust pipeline of future therapies.
DitchCarbon Score
How does Merck And Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merck And Co's score of 76 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merck And Co's reported carbon emissions
In 2023, Merck & Co., Inc., headquartered in the US, reported total greenhouse gas emissions of approximately 7,527,700,000 kg CO2e. This includes Scope 1 emissions of about 718,400,000 kg CO2e, Scope 2 emissions of approximately 184,200,000 kg CO2e, and significant Scope 3 emissions totalling around 6,184,100,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its operational greenhouse gas emissions (Scopes 1 and 2) by 46% by 2030, using 2019 as a baseline. Additionally, Merck has pledged to achieve carbon neutrality across its operations (Scopes 1 and 2) by 2025. Merck's long-term strategy includes a commitment to reach net-zero greenhouse gas emissions across its entire value chain by 2045. This includes a target to reduce absolute Scope 3 emissions by 30% by 2030. The company’s targets are aligned with the Science Based Targets initiative (SBTi), ensuring that their reduction goals are consistent with the global effort to limit warming to 1.5°C. Overall, Merck & Co. is actively working towards significant emissions reductions and has established a comprehensive framework to address its climate impact, demonstrating leadership in the pharmaceutical sector's response to climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Merck And Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
